npj Vaccines

Article	Citations
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates	519
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action	265
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2	200
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic	193
Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases	169
Protein-based antigen presentation platforms for nanoparticle vaccines	126
The use of viral vectors in vaccine development	118
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19	117
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents	109
Access to and equitable distribution of COVID-19 vaccine in low-income countries	97
Vaccines for human fungal diseases: close but still a long way to go	86
Extended interval BNT162b2 vaccination enhances peak antibody generation	86
Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation	84
Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel	81
Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines	75
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy	68
Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees	68
Is new dengue vaccine efficacy data a relief or cause for concern?	64
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models	63
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza	62
Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice	55
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus	54
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate	53
Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis	53
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination	51

A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection	50
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge	50
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses	49
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report	49
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets	48
Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge	47
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters	47
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates	47
“World in motion” – emulsion adjuvants rising to meet the pandemic challenges	47
Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells	46
SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses	45
The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control	43
Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters	41
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants	41
Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases	39
The shot, the message, and the messenger: COVID-19 vaccine acceptance in Latin America	39
Current status of monkeypox vaccines	39
A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses	39
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease	39
Challenges and developments in universal vaccine design against SARS-CoV-2 variants	39
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice	38
An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein	38
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates	38
Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage	37
The Streptococcus pyogenes vaccine landscape	36
A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice	36
Considerations for bioanalytical characterization and batch release of COVID-19 vaccines	35
The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization	34
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles	34
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect	33
Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant	33
KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine	33
Urgency and necessity of Epstein-Barr virus prophylactic vaccines	33
Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge	33
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability	33
Vaccination as a preventative measure contributing to immune fitness	32
ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge	32
Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies	31
Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine	30
Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development	30
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	29
Protein engineering strategies for rational immunogen design	29
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability	28
MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies	28
Benefit of COVID-19 vaccination accounting for potential risk compensation	28
Immune response against SARS-CoV-2 variants: the role of neutralization assays	28
Promoting versatile vaccine development for emerging pandemics	28
Sex-specific effects of aging on humoral immune responses to repeated influenza vaccination in older adults	27
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer	27
Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults	27

A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection	27
A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine	26
mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum	26
A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells	26
The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine	26
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	26
Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines	26
Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation	25
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination	25
Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis	25
Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity	25
Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination	25
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)	25
Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes	25
The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model	25
A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice	24
Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?	24
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2	24
Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge	24
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	23
A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial	23
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	23
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants	23
Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies	22
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy	22
The year that shaped the outcome of the OspA vaccine for human Lyme disease	22
Correlates of immunity to Group A Streptococcus: a pathway to vaccine development	22
Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination	22
Deimmunization of flagellin for repeated administration as a vaccine adjuvant	22
Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection	21
The rapid progress in COVID vaccine development and implementation	21
Force of infection: a determinant of vaccine efficacy?	21
An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission	21
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	21
Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine	20
A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection	20
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19	20
Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice	20
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19	20
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine	19
Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines	19
The advances of adjuvants in mRNA vaccines	19
Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients	19
A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars	19
The road to approved vaccines for respiratory syncytial virus	19
Rational development of a combined mRNA vaccine against COVID-19 and influenza	19
Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques	18
Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2	18
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2	18
Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance	18
Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial	18
Is partisan conflict over COVID-19 vaccination eroding support for childhood vaccine mandates?	18
Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa	17
The HSP70-fused foot-and-mouth disease epitope elicits cellular and humoral immunity and drives broad-spectrum protective efficacy	17
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore	17
An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection	17
An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats	17
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities	17
Toxoplasmosis vaccines: what we have and where to go?	17
Key advances in vaccine development for tuberculosis—success and challenges	17
MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge	17
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses	16
Revaccination with Bacille Calmette-Guérin (BCG) is associated with an increased risk of abscess and lymphadenopathy	16
High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers	16
Th17-related mammary immunity, but not a high systemic Th1 immune response is associated with protection against E. coli mastitis	16
Outlook of pandemic preparedness in a post-COVID-19 world	16
Pandemic-response adenoviral vector and RNA vaccine manufacturing	16
Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)	16
Assessment of African swine fever vaccine candidate ASFV-G-∆MGF in a reversion to virulence study	16
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico	16
Live-attenuated ME49Δcdpk3 strain of Toxoplasma gondii protects against acute and chronic toxoplasmosis	16
CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines	16
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines	16
Japanese encephalitis virus live attenuated vaccine strains display altered immunogenicity, virulence and genetic diversity	15
A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform	15
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	15
A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern	15
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant	15
Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets	15
Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230	15

Molecular interactions between parasite and mosquito during midgut invasion as targets to block malaria transmission	15
Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses	15
Links between fecal microbiota and the response to vaccination against influenza A virus in pigs	15
Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern	15
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola	15
Durable natural killer cell responses after heterologous two-dose Ebola vaccination	15
Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen	14
mRNA vaccines induce rapid antibody responses in mice	14
Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic	14
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S	14
Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children	14
Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice	14
Pneumococcal capsule blocks protection by immunization with conserved surface proteins	14
Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection	14
Haplotype-resolved de novo assembly of the Vero cell line genome	14
Onchocerca volvulus bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice	13
Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses	13
Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need	13
Understanding drivers of vaccine hesitancy among pregnant women in Nigeria: A longitudinal study	13
Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma	13
A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine	13
A potent, broadly protective vaccine against SARS-CoV-2 variants of concern	13
Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats	13
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs	13
Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion	12
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design	12
Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition	12
Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies	12
A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates	12
mRNA-LNP vaccination-based immunotherapy augments CD8+ T cell responses against HPV-positive oropharyngeal cancer	12
Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection	12
Enhanced isolation of influenza viruses in qualified cells improves the probability of well-matched vaccines	12
Neutralization of MERS coronavirus through a scalable nanoparticle vaccine	12
Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein	12
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum	12
Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant	12
Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques	12
Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia ΔtonB Δhcp1 live attenuated vaccines	12
Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver	12
ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys	12
Centrin-deficient Leishmania mexicana confers protection against Old World visceral leishmaniasis	12
Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine	12
A single-dose live attenuated chimeric vaccine candidate against Zika virus	12